Fitness & Wellness

First Patient Implanted in US Post-Approval Study for Genio Sleep Apnea Therapy

32 sec read82 views0 listens

A post-approval study, BREATHE, has begun enrolling patients to evaluate the long-term safety and effectiveness of a new leadless and battery-free hypoglossal nerve stimulation therapy for obstructive sleep apnea. This development is significant because it offers a potentially innovative treatment option for those struggling with OSA, which affects millions and can be difficult to manage. The study will follow up to 229 patients across multiple US centers over five years, providing valuable data on real-world performance of the Genio system.

Read the full article at Sleep Review

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & PharmaSep 1832 sec read

Two-Organ View of the Human Brain Emerges

New research indicates the human brain isn't a single organ, but rather two distinct nervous systems that evolved independently over hundreds of millions of years. This challenges a long-held developmental model and has significant implications for b...

Ali Nemati

AI & Machine LearningSep 923 sec read

Man Announces That He Has Synthesized a New Schizophrenia Treatment in His Garage, Based on a Formula Devised by ChatGPT

A biochemist named Douglas Yao has synthesized a potential schizophrenia treatment called PAC-3310 in his garage, using a formula devised by AI model ChatGPT. This development highlights the growing role of AI in drug discovery but raises significant...

Ali Nemati

Biotech & PharmaSep 822 sec read

Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

Biotech company Moonwalk Biosciences has raised $70 million to develop RNA interference (RNAi) therapies targeting obesity and cardiometabolic diseases. This funding will advance its lead candidate, MW101, into clinical trials by late 2027 and expand...

Ali Nemati